Table W1. Reported Cytokine Plasma Levels in Patients with Cancer.

Cytokine	Reported Plasma Concentration, mean (pg/ml)	Cancer Tested	References	Notes on Correlation
GM-CSF	0.32	Prostate	Adler et al. [1]	No correlation with stage
HGF	499.00 (PT)	Prostate	Gupta et al. [2]	Predictor of metastasis
	1,062.00 (Met)			
IL-6	0.36 (RL)	Colorectal	Kim et al. [3]	Increased risk when over RL
	1.94 (PT)	Prostate	Adler et al. [1]	Increased with stage and metastasis
	93.15 (Met)			
MCP-1	365.26	AML	Mazur et al. [4]	Increased over control
M-CSF	—*	Breast	Lawicki et al. [5]	Correlated with stage
	9700.00 (Met)		Scholl et al. [6]	Increased with metastasis and stage
	4200.00 (PT)			
	867.00 (Met)		McDermott et al. [7]	Increased with metastasis
	—*	Prostate	Ide et al. [8]	Increased with bone metastasis
	627.00 (Met)		McDermott et al. [7]	Increased with bone metastasis
	604.00	Head and neck	McDermott et al. [7]	Increased over control
MMP-1	700.00	Thyroid	Komorowski et al. [9]	No difference compared with control
MMP-13	15,200.00 (PT)	Prostate	Morgia et al. [10]	Increased with metastasis, decreased with treatment
	28,600.00 (Met)			
MMP-2	—*	Ovarian	Manenti et al. [11]	No difference compared with control
	839,000.00 (PT)	Prostate	Morgia et al. [10]	Increased with metastasis, decreased with treatment
	1,230,00.00 (Met)			
	568,900.00	Colorectal	Tutton et al. [12]	Decreased with treatment
	605,950.00	Thyroid	Komorowski et al. [9]	Increased over control
MMP-9	51,400.00 (RL)	NSCLC	Tamura et al. [13]	Increased with stage. Levels above RL correlate with LN metastasis
	—*	Ovarian	Manenti et al. [11]	Increased in cancer and nonmalignant patients
	—*	Breast and lung	Susskind et al. [14]	Increased in patients, decreased with RT
	48,600.00 (PT)	Prostate	Morgia et al. [10]	Increased with metastasis, decreased with treatment
	108,000.00 (Met)			
	97,300.00		Castellano et al. [15]	Increased with stage, decreased with treatment
	56,500.00	Colorectal	Tutton et al. [12]	Decreased with treatment
OPG	1717.00	Neoblastoma	Granchi et al. [16]	Decreased over control
	—*	Prostate, Lung and Breast	Mountzios et al. [17]	Increased with metastasis
OPN	170,600.00	Prostate	Castellano et al. [15]	Increased with stage, decreased with treatment
RANKL	41.40	Neuroblastoma	Granchi et al. [16]	Increased with stage, metastasis, and unfavorable pathohistology
SDF-1α	2448.00	Breast	Potter et al. [18]	
	2661.00 (RL)		Hassan et al. [19]	Increased metastasis below RL
				Increased with metastasis
	2717.00 (PT)	Multiple	Zannettino et al. [20]	
	3114.00 (Met)	Myeloma		
TGF-β1	4320.00	Breast	Ivanovic et al. [21]	Increased with stage and associated with metastasis
	—*		Decensi et al. [22]	Inverse correlation with disease recurrence
	3280.00 (RL)		Nikolic-Vukosavljevic et al. [23]	Levels above RL correlate with decreased survival
	15,500.00 (Met)	Prostate	Shariat et al. [24]	Increased with metastasis to LN and bone
	5200.00 (PT)			
	15,250.00 (Met)		Adler et al. [1]	Increased with metastasis
	2630.00	Breast and prostate	Baselga et al. [25]	Increased in patients, 1.4-fold higher than breast cancer patients
TIMP-1	240,000.00	Colorectal	Holten-Andersen et al. [26]	Increased in high stage
	292,000.00	Breast	Holten-Andersen et al. [26]	Advanced breast cancer
	108,700.00		Schrohl et al. [27]	
	133,000.00	Ovarian	Manenti et al. [11]	Increased over nonmalignant
	—*	Breast	Susskind et al. [14]	Increased in patients and remain high after RT
	378,000.00 (PT)	Lung		Lower than controls, Increased with treatment
	541,000.00 (Met)			
TIMP-2	29,800.00	Ovarian	Manenti et al. [11]	Increased over nonmalignant
	114,200.00	Thyroid	Komorowski et al. [9]	Increased over control
TNFα	2.24 (RL)	Colorectal	Kim et al. [3]	Increased risk when over RL
	3.95 (PT)	Prostate	Adler et al. [1]	Increased with stage and metastasis
	4.34 (Met)			
TPO	232.00	CLL	Koller et al. [28]	Increased over controls, Increased with stage
	—*	Lung	Werynska et al. [29]	Increased in patients with reactive thrombocytosis
uPAR	—*	Ovarian	Henic et al. [30]	Increased with stage, indicates poor prognosis
	1600.00 (PT)	Prostate	Shariat et al. [31]	Increased in metastasis, decreased with treatment
	2400.00 (Met)			
VEGF	316.80 (RL)	NSCLC	Tamura et al. [13]	Increased with stage. Levels above RL correlate with LN metastasis
	—*	Various	Wynendaele et al. [32]	Increased over controls
	109.10	Ovarian	Manenti et al. [11]	Significantly higher than nonmalignant patients
	31.30 (Met)	Prostate	Shariat et al. [33]	Increased with stage and metastasis
	9.91 (PT)			
	32.60	Breast	Burstein et al. [34]	Associated with decreased time to recurrence
	74.30	Thyroid	Komorowski et al. [9]	No difference compared with control

AML indicates acute myeloid leukemia; CLL, chronic lymphocytic leukemia; LN, lymph node; Met, metastasis; NSCLC, non–small cell lung carcinoma; PT, primary tumor; RL, reference level; RT, radiotherapy.
*No exact values reported.